Tuesday, 27 June 2017

Alder's migraine drug meets main goal in late-stage study

(Reuters) - Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.


No comments:

Post a Comment